Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm Prolias Licenses MiRNA IP from Cornell

NEW YORK (GenomeWeb News) – Molecular diagnostics company Prolias Technologies today announced it has licensed intellectual property covering microRNA-based diagnostics from Cornell University.

The technologies were developed at the Weill Cornell Medical College. The first series of IP includes a panel called Thymira that differentiates malignant from benign indeterminate thyroid nodules. Prolias, which said it anticipates commercially launching the panel in the coming months, also has licensed an algorithm to interpret results.

According to the New York-based company, more than 450,000 thyroid nodule biopsies are performed annually in the US to determine which ones are cancerous. Of that, about 30 percent are classified as indeterminate, requiring surgery and broader pathology for a complete diagnosis. About 75 percent of the surgically affected nodules, however, are ultimately classified as benign.

Thymira is aimed at eliminating the need for surgery to clarify nodules of indeterminate status, Prolias said.

In addition to Thymira, Prolias has licensed Armira, a miRNA technology to non-invasively monitor acute kidney rejection after transplantation. The company did not elaborate on its commercialization plans for Armira.

Financial terms of licensing deal were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.